A Lantheus deal = priceless, if done: As part
Post# of 155052
(Total Views: 675)
Posted On: 04/21/2024 2:01:05 AM
A Lantheus deal = priceless, if done:
As part of the Progenics Acquisition, the Company acquired the right to receive certain future milestone and royalty payments due to Progenics from
CytoDyn Inc. (“CytoDyn”) related to a prior sale of certain intellectual property. The Company has the right to receive $5.0 million upon regulatory
approval and a 5% royalty on net sales of approved products. The Company considers the contingent receivable a Level 3 instrument (one with significant
unobservable inputs) in the fair value hierarchy. The estimated fair value was determined based on probability adjusted discounted cash flows that included significant estimates and assumptions pertaining to regulatory events and sales targets. During the fourth quarter of 2022, the Company reduced the probability to zero as CytoDyn withdrew
their regulatory application. The most significant unobservable inputs are the probabilities of achieving regulatory approval of the development projects
and subsequent commercial success."
LANTHEUS HOLDINGS, INC.
2/22/24 10-K
Pg 99
________
This, forgotten Right/Royalty, i've had my fingers crossed for Mitch getting us a new deal. If "just" even securing a reduction of the 5%.
To me, this deal, has always been the true target for Cytodyn.
If Mitch pulls this off, (if even considering it -- which i would assume Cytodyn made it an SOW for him), it again won't matter if our share structure is even...2b shares, on "just" Chronic Inflammation.
Being this was early HIV days, i can't say i remember if it would now include Chronic indication. Maybe was not written strong enough.
If, if not, then Mitch would have leverage.
Will have to look back into the Cytodyn/Progenics.
It is alot different than the Samsung sutuation,
but my god, say a hypothetical 2.5% (50%) reduction even would be worth what ??.... woo
Shall see....
As part of the Progenics Acquisition, the Company acquired the right to receive certain future milestone and royalty payments due to Progenics from
CytoDyn Inc. (“CytoDyn”) related to a prior sale of certain intellectual property. The Company has the right to receive $5.0 million upon regulatory
approval and a 5% royalty on net sales of approved products. The Company considers the contingent receivable a Level 3 instrument (one with significant
unobservable inputs) in the fair value hierarchy. The estimated fair value was determined based on probability adjusted discounted cash flows that included significant estimates and assumptions pertaining to regulatory events and sales targets. During the fourth quarter of 2022, the Company reduced the probability to zero as CytoDyn withdrew
their regulatory application. The most significant unobservable inputs are the probabilities of achieving regulatory approval of the development projects
and subsequent commercial success."
LANTHEUS HOLDINGS, INC.
2/22/24 10-K
Pg 99
________
This, forgotten Right/Royalty, i've had my fingers crossed for Mitch getting us a new deal. If "just" even securing a reduction of the 5%.
To me, this deal, has always been the true target for Cytodyn.
If Mitch pulls this off, (if even considering it -- which i would assume Cytodyn made it an SOW for him), it again won't matter if our share structure is even...2b shares, on "just" Chronic Inflammation.
Being this was early HIV days, i can't say i remember if it would now include Chronic indication. Maybe was not written strong enough.
If, if not, then Mitch would have leverage.
Will have to look back into the Cytodyn/Progenics.
It is alot different than the Samsung sutuation,
but my god, say a hypothetical 2.5% (50%) reduction even would be worth what ??.... woo
Shall see....
(3)
(0)